These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25498311)

  • 1. Reforming private drug coverage in Canada: inefficient drug benefit design and the barriers to change in unionized settings.
    O'Brady S; Gagnon MA; Cassels A
    Health Policy; 2015 Feb; 119(2):224-31. PubMed ID: 25498311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs.
    Charbonneau M; Gagnon MA
    Health Policy; 2018 Dec; 122(12):1295-1301. PubMed ID: 30241797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing health care market reform through an insurance exchange: essential policy components, the public plan option, and other issues to consider.
    Fronstin P; Ross MN
    EBRI Issue Brief; 2009 Jun; (330):1-22. PubMed ID: 19545086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacy benefits: new concepts in plan design.
    Goff VV
    NHPF Issue Brief; 2002 Mar; (772):1-16. PubMed ID: 11915906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing employer-sponsored and federal exchange plans: wide variations in cost sharing for prescription drugs.
    Buttorff C; Andersen MS; Riggs KR; Alexander GC
    Health Aff (Millwood); 2015 Mar; 34(3):467-76. PubMed ID: 25732498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defined contribution health benefits.
    Fronstin P
    EBRI Issue Brief; 2001 Mar; (231):1-30. PubMed ID: 11291165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated cost of universal public coverage of prescription drugs in Canada.
    Morgan SG; Law M; Daw JR; Abraham L; Martin D
    CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care reform: perspectives from large employers.
    Darling H
    Health Aff (Millwood); 2010 Jun; 29(6):1220-4. PubMed ID: 20530359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An American approach to health system reform.
    Holahan J; Moon M; Welch WP; Zuckerman S
    JAMA; 1991 May; 265(19):2537-40. PubMed ID: 2020072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing an effective generic prescription drug program.
    Jones JD
    Benefits Q; 2003; 19(1):14-8. PubMed ID: 12608114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical policy reform in Canada: lessons from history.
    Boothe K
    Health Econ Policy Law; 2018 Jul; 13(3-4):299-322. PubMed ID: 29388519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will choice-based reform work for Medicare? Evidence from the Federal Employees Health Benefits Program.
    Florence CS; Atherly A; Thorpe KE
    Health Serv Res; 2006 Oct; 41(5):1741-61. PubMed ID: 16987300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognize the role of employers.
    French M
    Healthc Pap; 2004; 4(3):46-50; discussion 68-72. PubMed ID: 15114069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Battle for Universal Pharmacare in Canada Comment on "Universal Pharmacare in Canada".
    Gagnon MA
    Int J Health Policy Manag; 2021 Mar; 10(3):168-171. PubMed ID: 32610789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-insuring employee health benefits.
    Garfinkel SA
    Med Care Res Rev; 1995 Nov; 52(4):475-91. PubMed ID: 10153310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for health care cost containment.
    Mitchell GA
    Empl Benefits J; 1995 Jun; 20(2):18-22. PubMed ID: 10142520
    [No Abstract]   [Full Text] [Related]  

  • 18. Managing the intricate Web of prescription drugs.
    Eber BL
    Benefits Q; 2003; 19(1):45-50. PubMed ID: 12608118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seeking value in working with pharmacy benefit managers.
    Vogenberg FR; Sica JM
    Benefits Q; 2003; 19(1):7-12. PubMed ID: 12608113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.